profit from every $100 of sales.
$0$100
Illumina
$212.93-0.92% today
+73.7% in 1 year
1-year low $114.441-year high $293.69
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $37.88 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Illumina sold, what it kept, and what it did with the cash.
Sales went from $4.58 billion in 2022 to $4.34 billion in 2025, with $850 million of profit last year.
SalesProfit
Illumina handed back 80% of the cash it generated last year.
Buybacks $742M
Free cash flow 2025$931M
Bought back its own shares$742M
Paid as dividends–
Cash vs. debt$1.4B vs. $2.6B
Illumina vs. similar companies
Illumina grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Illumina | 37.9× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet | ||
 Exact Sciences | No profit yet |
AI analysis
An AI analyst reads Illumina's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 3,239 | 4,526 | 4,584 | 4,504 | 4,372 | 4,343 | |
| 2,203 | 3,154 | 2,972 | 2,744 | 2,861 | 2,870 | |
| 580 | -123 | 354 | -222 | 600 | 817 | |
| 1,092 | 1,196 | -3,916 | -608 | -725 | 1,457 | |
| 656 | 762 | -4,404 | -1,161 | -1,223 | 850 | |
| 4.45 | 5.04 | -28.00 | -7.34 | -7.69 | 5.45 | |
| 68.0% | 69.7% | 64.8% | 60.9% | 65.4% | 66.1% | |
| 17.9% | -2.7% | 7.7% | -4.9% | 13.7% | 18.8% | |
| 20.3% | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 7,585 | 15,217 | 12,252 | 10,111 | 6,303 | 6,644 |
| Cash | 1,810 | 1,232 | 2,011 | 1,048 | 1,127 | 1,418 |
| Total debt | – | – | 3,555 | 2,262 | 2,622 | 2,553 |
| Total liabilities | – | – | 5,653 | 4,366 | 3,930 | 3,921 |
| 4,694 | 10,740 | 6,599 | 5,745 | 2,373 | 2,723 | |
| 148 | 151 | 157 | 158 | 159 | 156 | |
| 15.2% | 7.0% | -33.5% | -10.3% | -17.1% | 17.8% | |
| 14.0% | 7.1% | -66.7% | -20.2% | -51.5% | 31.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,080 | 545 | 392 | 478 | 837 | 1,079 | |
| 189 | 208 | 286 | 195 | 128 | 148 | |
| 891 | 337 | 106 | 283 | 709 | 931 | |
| Dividends paid | – | – | – | – | – | – |
| 736 | 0 | 0 | 0 | 116 | 742 | |
| 194 | 754 | 366 | 380 | 370 | 275 |
Valuation
- 37.9×
- 41.0×
- 9.15
- 8.1×
- 7.4×
- 34.6×
- 22.9×
- 2.9%
- 2.6%
- 0.0%
Profitability
- 66.1%
- 18.8%
- 19.6%
- 27.6%
- 13.8%
- -12.1%
- 34.0%
- 13.0%
- 18.9%
- 21.6%
Growth
- +6.0%
- +4.1%
- +31.3%
- –
- +0.8%
Financial health
- 1.1×
- 0.92
- 37.6%
- 12.4×
- 1.75
- 1.36
- 0.67
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 15%of 959
Top 26%of 888
Bottom 33%of 599
Bottom 33%of 889
Top 36%of 987
What analysts expect
- Average price target
- $147.38
- Range
- $122.00 – $170.00
- 6 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 1.15 | 1.05 | +9.5% |
| Feb 5, 2026 | 1.35 | 1.24 | +8.9% |
| Oct 30, 2025 | 1.34 | 1.17 | +14.5% |
| Jul 31, 2025 | 1.19 | 1.02 | +16.7% |
| May 8, 2025 | 0.97 | 0.94 | +3.2% |
| Feb 6, 2025 | 0.86 | 0.92 | −6.5% |
| Nov 4, 2024 | 1.14 | 0.88 | +29.7% |
| Aug 6, 2024 | 0.36 | 0.11 | +228.5% |
News
Global Clinical Genomics Software Market Report 2026 | Capitalize on 14.8% CAGR Through 2030 as Google, Microsoft, NVIDIA and Illumina Scale AI, Cloud and Precision MedicineYahoo Finance · Nov 9, 2026What Sent Illumina Stock Lower?Yahoo Finance · Nov 2, 2026Global Clinical Knowledge Graphs for Genomics Market Report 2026 | Capitalize on 20.7% CAGR as Microsoft, IBM, Illumina and Genomenon Scale AI, Cloud and Precision MedicineYahoo Finance · Oct 30, 2026Illumina forecasts 2026 EPS of $5.40-$5.45 while raising revenue outlook to $4.64B-$4.66BSeeking Alpha · Oct 29, 2026BE, P, ILMN Join S&P 500; LNG Misses Out — Bloom Energy Stock Gains While Cheniere Energy SlipsYahoo Finance · Sep 4, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
44No pass
Benjamin Graham
21No pass
Philip Fisher
51No pass
Peter Lynch
25No pass
Joel Greenblatt
14No pass
Charlie Munger
46No pass
Terry Smith
48No pass
Questions about Illumina
Is Illumina a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Illumina AI analysis
What does Illumina do?
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. It is in Medical - Diagnostics & Research, based in San Diego, CA, United States, with 8,600 employees.
Does Illumina pay a dividend?
No. Illumina does not pay a dividend at the moment; in 2025 it returned $742 million to shareholders by buying back its own shares.
Is Illumina stock halal?
Yes. Illumina passes our halal screen: its business is permitted and its debt is 8% of its market value, under the 30% limit. How we check
How has Illumina stock done over the past year?
Up 73.7% over the past twelve months, to $212.93. It traded between $114.44 and $293.69 and is 27.5% below its high.
Who are Illumina's competitors?
The largest listed companies in the same industry are Labcorp Holdings, Quest Diagnostics, Guardant Health and Exact Sciences. The peers table on this page compares their profit, growth and price with Illumina's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.